A Study of MK0476 in the Treatment of Asthma Patients Aged 2-5 Years

A study to determine the efficacy of MK0476 in the Treatment of Asthmatic Patients Aged 2 to 5 Years...

Date First Received: June 17, 2008

Last Updated: June 18, 2008

Verified by: Merck, June 2008

Clinical Trial Phase: Phase 3 | Start Date: 

Overall Status: Completed

Estimated Enrollment: 500

Brief Summary

Official Title: “A Multicenter, Double-Blind, Placebo-Controlled, Randomized, Parallel-Group, Study to Determine the Efficacy of Montelukast in the Treatment of Exacerbations in Asthmatic Patients Aged 2-to-5 Years”

Condition Keyword(s):

A study to determine the efficacy of MK0476 in the Treatment of Asthmatic Patients Aged 2 to 5 Years.

Study Type: Interventional

Study Design: Treatment, Randomized, Double Blind (Subject, Investigator), Placebo Control, Parallel Assignment, Efficacy Study

Study Primary Completion Date: December 2002

Intervention(s) in this Clinical Trial

  • Drug: montelukast
    • One montelukast 4-mg chewable tablet (CT) administered once daily at bedtime. Duration of Treatment: 48 Weeks
  • Drug: placebo (unspecified)
    • Matching-image Montelukast placebo. Duration of Treatment: 48 Weeks

Arms, Groups and Cohorts in this Clinical Trial

  • Experimental: 1
    • Drug
  • Placebo Comparator: 2
    • Pbo

Outcome Measures for this Clinical Trial

Primary Measures

  • asthma episodes in 2 - 5 year old children
    • Time Frame: at 12 months
      Safety Issue?: No

Secondary Measures

  • the number of treatments and duration of asthma episodes
    • Time Frame: at 12 months
      Safety Issue?: No

Criteria for Participation in this Clinical Trial

Inclusion Criteria:

  • Male or Female between and including the ages of 2 and 5 years
  • Patient was treated with steroids for an asthma episode in the last 3 months
  • Patient was admitted to the hospital or emergency room in the last 3 months
  • Patient is able to chew a tablet

Exclusion Criteria:

  • Patient has been in a research study in the past 4 weeks
  • Patient has visited the emergency room for an asthma episode in the past week
  • Patients has a history of stomach, heart, liver, nerve, kidney or blood disease

Gender Eligibility for this Clinical Trial: Both

Minimum Age for this Clinical Trial: 2 Years

Maximum Age for this Clinical Trial: 5 Years

Are Healthy Volunteers Accepted for this Clinical Trial?: No

Clinical Trial Sponsor Information

Lead Sponsor: Merck

Overall Clinical Trial Officials and Contacts

Medical Monitor Study Director Merck  

Additional Information

Information obtained from ClinicalTrials.gov on September 05, 2008

Link to the current ClinicalTrials.gov record. http://clinicaltrials.gov/show/NCT00700661

Study ID Number: 2007_572

ClinicalTrials.gov Identifier: NCT00700661

Health Authority: Belgium: Directorate general for the protection of Public health: Medicines

MedWatch - FDA maintained medical product safety Information

PhRMA Clinical Study Results Database - web-based repository for clinical study results

Merck: Patient & Caregiver U.S. Product Web Site

Clinical Trials Authorship and Review

Clinical Trials content is provided directly by the U.S. National Institutes of Health via ClinicalTrials.gov and is not reviewed separately by ClinicalTrialsFeeds.org. Every page of specific clinical trials information contains a unique identifier which can be used to find further details directly from the National Institutes of Health.